Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10267432 | 0.88 | KMT2A (0.46) | MEN1KMT2ALMNATSHRMAPT | |
| SCHEMBL20294761 | 0.88 | HRH3 (0.38) | SMN1; SMN2GFERHTTMEN1KMT2A | |
| SCHEMBL25219317 | 0.87 | SMN1; SMN2 (0.43) | SMN1; SMN2GFERHTTMEN1KMT2A | |
| SCHEMBL22636528 | 0.86 | S1PR1 (0.50) | SMN1; SMN2GFERTSHRMAPTREV1 | |
| SCHEMBL24979321 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2GFERHTTMEN1KMT2A | |
| SCHEMBL29429852 | 0.84 | MAPT (0.43) | SMN1; SMN2MEN1KMT2ATSHRMAPT | |
| SCHEMBL30971835 | 0.83 | DGAT1 (0.47) | SMN1; SMN2KMT2AALDH1A1NPSR1 | |
| SCHEMBL27396001 | 0.83 | DGAT1 (0.47) | SMN1; SMN2KMT2AALDH1A1NPSR1 | |
| SCHEMBL23538213 | 0.81 | DEGS1 (0.40) | SMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL18441078 | 0.81 | OPRM1 (0.43) | SMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | SMN1; SMN2 4701/4885GFER 2049/4885HTT 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.